No Data
Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation?
Codexis (NASDAQ:CDXS) Delivers Shareholders Respectable 89% Return Over 1 Year, Surging 16% in the Last Week Alone
Caribou Biosciences Hires CFO From Codexis
Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Synthetic Biology Focused Insights Report 2024-2029 With Competitive Analysis of 38 Vendors - Agilent, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific Lead - ResearchAndMarkets.com
Cantor Fitzgerald Maintains Codexis(CDXS.US) With Buy Rating, Maintains Target Price $11